From Clinical Trials to Real-world Practice, Experts Examine the Best Options for TNBC

摘要

CancerNetwork? recently hosted a first-of-its-kind Tweet Chat with cohosts Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD. Together, they reviewed a patient case of a 52-year-old woman with a diagnosis of stage HA triple-negative breast cancer (TNBC) and went into detail regarding treatment options for the metastatic population. Rugo, a professor of medicine and director of Breast Oncology and Clinical Trials Education at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, and Tarantino, a clinical research fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, also examined the use of neoadjuvant therapeutics for early disease and potential adjuvant therapy-sparing regimens. During the live chat, both experts detailed the impact of antibody-drug conjugates (ADCs) on survival outcomes and the best approach for treating patients following disease recurrence after first-line therapy.